Vetter works towards a sustainable energy supply
All German sites of the pharmaceutical service provider will be supplied with green electricity.
Vetter has reached another important milestone regarding sustainability. Beginning immediately, all German sites of the company will be supplied with only CO2 neutral energy from certified renewable energy sources.
As a partner of biotechnology and pharmaceutical customers both large and small, Vetter has been meeting high international sustainability requirements for many years. The company is certified according to the standards for environmental protection ISO 14001, energy management ISO 50001, as well as occupational health and safety BS OHSAS 18001.
“Sustainability is a central pillar of Vetter’s corporate philosophy and our stance on this subject is firmly anchored within our organization. The supply of our German sites with green electricity is an important part of our company-wide program for environmental protection, energy management, and occupational health and safety,” explains Managing Director Thomas Otto. “Our aim is to act holistically and develop our multi-faceted initiatives in these areas on a continuous basis.”
The next milestone has already been set. Within the next 10 years, Vetter plans to offset the company-wide use of natural gas, making it completely CO2 neutral. Unavoidable CO2 emissions are offset by investments in high-quality climate protection projects.
The largest sustainability project the CDMO recently implemented is at its state-of-the-art center for visual inspection and logistics, which received the international industry prize Facility of the Year Award (FOYA) in 2018 as a Facility of the Future. The site consequently realizes a sustainable energy concept specifically developed by Vetter. This includes the operation of a modern, environmentally friendly block heating and power plant, the use of geothermal energy and the comprehensive use of excess energy, as well as powerful photovoltaic systems, all of which are combined in an energy-efficient manner.
The company-wide EHS program also includes actions for sustainable, resource-efficient management, the promotion of healthy working conditions, and regular training for all staff members to raise their individual awareness of responsible behaviour.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance